Sustained Viral Response and Hematological Adverse Events During Chronic Hepatitis C Infection Treatment by El-Shabrawi, Mortada & Isa, Mona
KOWSAR
                            www.HepatMon.com
Sustained Viral Response and Hematological Adverse Events During 
Chronic Hepatitis C Infection Treatment
 Mortada  El-Shabrawi  1*,   Mona Isa 1 
1 Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
ARTICLE INFO
Article history:
Received: 19 Jan 2012
Revised: 25 Jan 2012
Accepted: 01 Feb 2012
Keywords:
 Infection
 Hepatitis  C
 Treatment
Article type:
 Letter to Editor
  Please cite this paper as: 
El-Shabrawi M, Isa M. Sustained Viral Response and Hematologi-
cal Adverse Events During Chronic Hepatitis C Infection Treat-
ment. Hepat Mon. 2012;12(2):122-3. DOI: 10.5812/hepatmon.831
Copyright  c 2012 Kowsar M. P. Co. All rights reserved. 
Hepat Mon. 2012;12(2):122-123. DOI: 10.5812/hepatmon.831
* Corresponding author: Mortada Hassan El-Shabrawi, 3 Nablos St. oﬀ 
Shehab St. Mohandesseen, Cairo 12411, Egypt. Tell: +20-235721790, Fax: +20-
237619012, E-mail: melshabrawi@medicine.cu.edu.eg; 
mortada_elshabrawi@yahoo.com
DOI: 10.5812/hepatmon.831
Copyright  c2012 Kowsar M.P.Co.  All rights reserved.
Dear Editor,
Hepatitis C virus (HCV), as a causative agent of chronic 
liver disease, has infected approximately 175 million 
people (almost 3%) of the world’s population; and 3 to 4 
million new cases are added to this ﬁgure annually (1). 
Chronic HCV infection may progress to severe outcomes 
in the form of cirrhosis and hepatocellular carcinoma 
(HCC) (2). Currently, there is no eﬀective HCV vaccine 
on the horizon due to a lack of a susceptible small ani-
mal model, an absence of neutralizing antibodies, and a 
high degree of viral genomic diversity and mutagenicity; 
therefore, successful treatment of HCV infection is very 
much needed. A few years ago, the standard of care (SOC) 
for chronic HCV infection consisted of subcutaneous 
injection of conventional Interferon (IFN)-α-2, 3 times 
per week, plus an oral, daily dose of Ribavirin (RBV) for 
24 to 48 weeks (2, 3). This therapy is not ideal because of 
a very low sustained virologic response [(SVR) i.e., HCV 
RNA undetectable 6 months after the end of treatment]. 
The current SOC consists of pegylated INF-α-2 once a 
week plus daily RBV for 24 to 72 weeks (4). This treatment 
aims to achieve a high SVR (5); however, diﬀerent people 
respond diﬀerently to this SOC regimen depending on 
many factors, particularly the age, sex, and ethnicity 
of the patient; the duration of infection; adiposity; the 
degree of aminotransferase elevation; HCV genotype; 
pretreatment viral load; and single nucleotide poly-
morphisms of interleukin-28B gene (6). Recently, oral 
protease inhibitors ( e.g., telaprevir or boceprevir) have 
been added as direct-acting antivirals to the SOC treat-
ment as a triple therapy, particularly in patients with 
HCV genotype 1 (7). We were interested in Pawlowska et 
al.’s study, which examined correlations between the 
hematological adverse events and the SVR in children 
undergoing therapy for chronic HCV infection (8). Spe-
ciﬁcally, Pawlowska et al. assessed the interdependence 
of the SVR and the hematological characteristics (leu-
kocyte count, platelet count, and hemoglobin levels) in 
patients with chronic HCV infection during treatment 
with IFN and RBV. They divided their sample of children 
into two groups: patients in Group I were treated with 
conventional IFN-α-2b plus RBV, and patients in Group II 
were treated with pegylated IFN-α-2b plus RBV. They con-
cluded that mild decreases in hemoglobin levels, leuko-
cyte counts, and platelet counts during treatment with 
IFN and RBV in children with chronic HCV infection may 
be factors associated with SVR induction. Hemoglobin 
levels decreased signiﬁcantly in patients who achieved 123
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SVR compared to the nonresponders in both groups. In 
a similar study by Sievert et al. (9) the virologic responses 
were also higher in anemic patients than in patients who 
did not develop anemia. After 12 weeks of therapy, the 
leukocyte and platelet counts were signiﬁcantly lower in 
children treated with pegylated IFN-α-2b plus RBV than 
in those treated with conventional IFN plus RBV (8). The 
hematological toxicity that occurs during therapy can re-
sult in modiﬁcations in dosage or even, in the worst-case 
scenario, withdrawing INF therapy, which decreases the 
chances of successful therapy and increases the risk of 
impaired liver function with cirrhosis and HCC as poten-
tial consequences (10). Two studies have suggested that 
pegylated INF therapy combined with Danazol could be 
used to eﬀectively treat patients suﬀering from HCV-re-
lated thrombocytopenia; this combined therapy avoids 
temporarily reducing or deﬁnitively stopping pegylated 
INF treatment and increases platelet levels (10, 11). The lit-
erature has clearly established that the rate of SVR with 
pegylated INF and RBV is comparatively higher in pa-
tients with genotypes 2 and 3 (80%) than in patients with 
genotypes 1 or 4 (40–50%) (4) . Despite achieving a higher 
SVR rate, one of the drawbacks of pegylated  INF is that 
it is least 25 times more expensive than conventional in-
terferon, making it unaﬀordable for many poor people 
in developing countries (5). Suwantarat et al. found that 
chronic HCV-infected patients with SVR had signiﬁcantly 
lower white blood cell and platelet counts at the end of 
treatment compared to those without SVR. These ﬁnd-
ings suggest that patients who develop leucopenia or 
thrombocytopenia during interferon treatment respond 
well to the therapy, and these side eﬀects, if not severe, 
may not be reasons to withhold or reduce the dose of the 
treatment. They hypothesized that the greater cytopenia 
might be an indication of greater tumor necrosis factor 
activity in a speciﬁc treatment recipient, which trans-
lates into a higher SVR (12).
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